Arna Pharma and Slate Run Pharma Form Joint Venture

New platform aims to expand specialized generics and branded products in the U.S. market

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Arna Pharma Inc. and Slate Run Pharmaceuticals have signed a memorandum of understanding to create a joint venture focused on building a scaled-up U.S. specialty pharmaceutical platform. The new entity will leverage Arna's development capabilities and portfolio expansion strategy with Slate Run's established U.S. commercial, regulatory, and supply chain infrastructure.

Why it matters

The joint venture represents a strategic move to create a stronger specialty pharmaceutical player in the U.S. market, combining complementary strengths to expand access to branded products, 505(b)(2) medicines, and specialized generics across high-value therapeutic segments.

The details

The new joint venture will be well-positioned to efficiently scale branded and specialized products across the U.S. market, with Arna Pharma contributing its development expertise and Slate Run providing its proven commercial and operational infrastructure. The combined organization aims to maintain high standards of regulatory compliance, product quality, and patient care as it executes its growth strategy.

  • The joint venture agreement was signed on February 26, 2026.

The players

Arna Pharma Inc.

A pharmaceutical company founded in 2024 with a focus on innovation and patient outcomes, offering end-to-end capabilities from formulation development to global commercialization, with a portfolio emphasizing niche dosage forms and treatments for rare and underserved diseases.

Slate Run Pharmaceuticals

A generic pharmaceutical company founded in 2014 with a strong and expanding presence in the U.S. market, led by a seasoned leadership team with extensive industry experience across commercial operations, regulatory affairs, quality, and supply chain management.

Ram Iyer

Senior Vice President of Arna Pharma Inc.

Michael Plessinger

CEO of Slate Run Pharmaceuticals

Got photos? Submit your photos here. ›

What they’re saying

“This represents a significant milestone for Arna Pharma and a powerful step forward in our long-term strategy. By combining Arna's development expertise with Slate Run's proven U.S. commercial and operational infrastructure, we have created a platform that is uniquely positioned to expand specialized generics in high-value therapeutic segments and accelerate market access, reimbursement, and physician engagement.”

— Ram Iyer, Senior Vice President of Arna Pharma Inc. (PRNewswire)

“We are excited to unite our organizations and begin this next chapter together. This combination strengthens our ability to execute, expand our portfolio, and continue to serve as a trusted U.S. partner for the industry.”

— Michael Plessinger, CEO of Slate Run Pharmaceuticals (PRNewswire)

What’s next

The leadership teams from Arna Pharma and Slate Run Pharmaceuticals will work closely to ensure a seamless integration, maintain operational continuity, and uphold the highest standards of regulatory compliance, product quality, and patient care as they execute the joint venture's growth strategy.

The takeaway

The formation of this joint venture between Arna Pharma and Slate Run Pharmaceuticals creates a stronger, more diversified specialty pharmaceutical platform in the U.S. market, leveraging complementary strengths to expand access to innovative branded products and specialized generics across high-value therapeutic areas.